Herantis Pharma Oyj (HRPMF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Herantis Pharma Oyj (HRPMF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Herantis Pharma Oyj (HRPMF) Resumen de Asistencia Médica y Tuberías
Herantis Pharma Oyj, a Finnish biotechnology company, specializes in developing CDNF-based therapies for Parkinson's disease, with lead candidates HER-096 and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) in preclinical and Phase I stages, respectively, positioning them in the competitive neurodegenerative disease treatment landscape.
Tesis de Inversión
Herantis Pharma Oyj presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on CDNF-based therapies for Parkinson's disease addresses a significant unmet medical need. Key value drivers include the successful advancement of HER-096 through preclinical development and positive results from the Phase I study of rhCDNF. The company's market capitalization is approximately $0.06 billion, and it currently has a negative P/E ratio of -6.84, reflecting its pre-revenue status. Growth catalysts include the progression of HER-096 into clinical trials and potential partnerships for further development and commercialization. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding. The company's small size and limited resources also pose challenges. Investors should carefully consider the inherent risks and uncertainties associated with biotechnology investments before investing in Herantis Pharma Oyj.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Herantis Pharma Oyj is focused on developing disease-modifying therapies for Parkinson's disease (PD).
- The lead product candidate, HER-096, is in preclinical development as a potential treatment for PD and other neurodegenerative diseases.
- Recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) is in Phase I clinical study in patients with PD.
- The company's market capitalization is approximately $0.06 billion.
- Herantis Pharma Oyj has a negative P/E ratio of -6.84, reflecting its pre-revenue status.
Competidores y Pares
Fortalezas
- Proprietary CDNF-based technology platform.
- Lead product candidates targeting a significant unmet medical need.
- Experienced management team with expertise in drug development.
- Phase I clinical study underway for rhCDNF.
Debilidades
- Limited financial resources.
- Small company size with limited infrastructure.
- Dependence on successful clinical trial outcomes.
- High risk associated with biotechnology investments.
Catalizadores
- Upcoming: Interim data release from the Phase I clinical study of rhCDNF expected in late 2026.
- Upcoming: Potential initiation of Phase I clinical trials for HER-096 within the next 1-2 years, pending funding and regulatory approvals.
- Ongoing: Active pursuit of strategic partnerships for development and commercialization.
- Ongoing: Preclinical studies evaluating the efficacy of CDNF in other neurodegenerative diseases.
- Ongoing: Efforts to secure additional funding through grants, equity offerings, or debt financing.
Riesgos
- Potential: Clinical trial failures for HER-096 and rhCDNF.
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Ongoing: Competition from other companies developing Parkinson's therapies.
- Ongoing: Need for additional funding and potential dilution of existing shareholders.
- Potential: Limited financial resources and small company size.
Oportunidades de crecimiento
- Advancement of HER-096 into Clinical Trials: The successful progression of HER-096, the advanced small and synthetic chemical peptidomimetic version of xCDNF, into clinical trials represents a significant growth opportunity. Positive preclinical data suggest its potential as a disease-modifying therapy for Parkinson's. The timeline for initiating Phase I trials is projected within the next 1-2 years, contingent on securing funding and regulatory approvals. The market for effective Parkinson's treatments is estimated to reach $5.6 billion by 2027, offering a substantial commercial opportunity.
- Positive Results from rhCDNF Phase I Study: Positive outcomes from the ongoing Phase I clinical study of recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) could serve as a major catalyst for growth. Demonstrating safety and preliminary efficacy in patients with Parkinson's disease would validate the CDNF-based approach and attract potential partners. Interim data is expected in late 2026, with final results anticipated in 2027. Success in this trial could lead to further clinical development and eventual commercialization.
- Strategic Partnerships for Development and Commercialization: Forming strategic partnerships with larger pharmaceutical companies or biotechnology firms could accelerate the development and commercialization of Herantis Pharma's pipeline. Collaborations could provide access to funding, expertise, and established distribution networks. The company is actively seeking potential partners, with discussions ongoing with several interested parties. A partnership agreement is anticipated within the next 12-18 months, which would significantly enhance the company's growth prospects.
- Expansion into Other Neurodegenerative Diseases: Leveraging the CDNF platform to develop therapies for other neurodegenerative diseases, such as Alzheimer's and Amyotrophic Lateral Sclerosis (ALS), represents a long-term growth opportunity. While Parkinson's disease is the primary focus, the potential of CDNF extends to other conditions characterized by neuronal damage and loss. Preclinical studies are underway to evaluate the efficacy of CDNF in these indications. Expansion into new therapeutic areas could significantly broaden the company's market reach and revenue potential.
- Securing Additional Funding to Support Pipeline Development: Securing additional funding through grants, equity offerings, or debt financing is crucial to support the continued development of Herantis Pharma's pipeline. The company requires significant capital to advance HER-096 into clinical trials and to continue the Phase I study of rhCDNF. The company is actively pursuing various funding options, with the goal of securing sufficient capital to fund its operations for the next 2-3 years. Successful fundraising would enable the company to execute its development plans and achieve key milestones.
Oportunidades
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into other neurodegenerative diseases.
- Positive clinical trial results for HER-096 and rhCDNF.
- Securing additional funding to support pipeline development.
Amenazas
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other companies developing Parkinson's therapies.
- Need for additional funding and potential dilution of existing shareholders.
Ventajas competitivas
- Proprietary CDNF-based technology platform.
- Intellectual property protection for HER-096 and rhCDNF.
- First-mover advantage in developing CDNF-based therapies for Parkinson's disease.
Acerca de HRPMF
Herantis Pharma Oyj, founded in 2008 and based in Espoo, Finland, is a biotechnology company dedicated to developing disease-modifying therapies for Parkinson's disease (PD). The company's primary focus is on harnessing the potential of Cerebral Dopamine Neurotrophic Factor (CDNF) to address the unmet needs in PD treatment. Their lead product pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate, and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical study in patients with PD. Herantis Pharma's strategy centers on creating innovative therapies that can protect and restore dopamine neurons, offering a potentially more effective approach compared to symptomatic treatments. The company is committed to advancing its pipeline through rigorous preclinical and clinical development, with the ultimate goal of providing transformative treatments for individuals affected by Parkinson's disease and other neurodegenerative conditions. The company operates primarily in Finland, focusing its research and development efforts on CDNF-based therapies.
Qué hacen
- Develop disease-modifying therapies for Parkinson's disease.
- Focus on Cerebral Dopamine Neurotrophic Factor (CDNF)-based therapies.
- Advance HER-096, a preclinical xCDNF candidate, for treating Parkinson's and other neurodegenerative diseases.
- Conduct Phase I clinical study of recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) in Parkinson's patients.
- Research and develop innovative therapies to protect and restore dopamine neurons.
- Seek strategic partnerships for development and commercialization of their pipeline.
Modelo de Negocio
- Develop and out-license novel therapeutics.
- Focus on unmet needs in Parkinson's disease treatment.
- Generate revenue through partnerships and potential future product sales.
Contexto de la Industria
Herantis Pharma Oyj operates within the competitive biotechnology industry, specifically targeting neurodegenerative diseases like Parkinson's. The market for Parkinson's disease treatments is substantial and growing, driven by an aging population and increasing prevalence. Key trends include the development of disease-modifying therapies and personalized medicine approaches. Competitors include companies like BioSpecifics Technologies Corp (BSTG), which focuses on collagenase-based therapies, and other firms developing novel treatments for neurological disorders. Herantis Pharma aims to differentiate itself through its CDNF-based approach, which has the potential to protect and restore dopamine neurons.
Clientes Clave
- Future patients with Parkinson's disease.
- Potential pharmaceutical partners.
- Healthcare providers treating neurodegenerative diseases.
Finanzas
Gráfico e información
Precio de la acción de Herantis Pharma Oyj (HRPMF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para HRPMF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para HRPMF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para HRPMF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de HRPMF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Antti Vuolanto D.Sc. (Tech)
Chief Executive Officer
Antti Vuolanto holds a D.Sc. (Tech) degree and has extensive experience in the biotechnology industry. His background includes leadership roles in various pharmaceutical and biotech companies, where he focused on drug development, clinical trials, and commercialization strategies. He has a proven track record of successfully advancing drug candidates through the development pipeline and securing regulatory approvals. Vuolanto's expertise spans across multiple therapeutic areas, with a particular emphasis on neurodegenerative diseases.
Historial: Since becoming CEO of Herantis Pharma Oyj, Antti Vuolanto has focused on advancing the company's pipeline of CDNF-based therapies for Parkinson's disease. He has overseen the progression of HER-096 into preclinical development and the ongoing Phase I study of rhCDNF. Under his leadership, the company has also sought strategic partnerships to accelerate development and commercialization. Vuolanto has successfully managed the company's limited resources and secured funding to support its operations.
Información del mercado OTC de HRPMF
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading activity can be sporadic. These securities often carry a higher degree of risk due to the lack of regulatory oversight and transparency compared to securities listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited or no financial disclosure requirements.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Difficulty in obtaining accurate and timely information.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review available financial information, if any.
- Assess the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Consult with a qualified financial advisor.
- Be aware of the risks associated with OTC investments.
- Company's incorporation in Finland, a country with strong corporate governance standards.
- Focus on developing therapies for a serious medical condition (Parkinson's disease).
- Ongoing Phase I clinical study for rhCDNF.
- CEO with relevant experience and qualifications.
- Presence of intellectual property protection for key assets.
Acciones de Herantis Pharma Oyj: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar HRPMF?
Herantis Pharma Oyj (HRPMF) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Proprietary CDNF-based technology platform.. Riesgo principal a monitorear: Potential: Clinical trial failures for HER-096 and rhCDNF.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de HRPMF?
HRPMF actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de HRPMF?
Los precios de HRPMF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre HRPMF?
La cobertura de analistas para HRPMF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en HRPMF?
Las categorías de riesgo para HRPMF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures for HER-096 and rhCDNF.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de HRPMF?
La relación P/E para HRPMF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está HRPMF sobrevalorada o infravalorada?
Determinar si Herantis Pharma Oyj (HRPMF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de HRPMF?
Herantis Pharma Oyj (HRPMF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis pending for HRPMF.